China’s Heavyweight Pharma Goes Private, and into Biotech
By Kristine Yang
Wednesday, September 11, 2013
SHANGHAI – When it went public in April 2007, Simcere Pharmaceutical Group quickly became the largest Chinese pharmaceutical listed in the U.S. Despite a good early performance, the stock never lived up to its promise. The firm’s share price crashed to below $5 after the global financial crisis and has been lingering at below $10 since late 2011 . Simcere, originally a maker of generics that has expanded into biologicals, will go private before the end of the year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.